intROdUctiOn
Costello syndrome (OMIM# 218040) is a rare disorder first described 40 years ago by a New Zealand pediatrician 1,2 based on its distinctive phenotype. Characteristic findings include coarse facial features, intellectual disability, cardiac problems (typically cardiac hypertrophy, less commonly, atrial tachycardia, or pulmonic stenosis), and severe failure-to-thrive with short stature. 3 The predisposition to neoplasia encompasses a spectrum from benign wart-like skin lesions termed papillomata to malignant tumors including rhabdomyosarcoma, neuroblastoma, and transitional cell carcinoma of the bladder. 4 The identification of activating heterozygous germline mutations in the proto-oncogene HRAS in individuals with Costello syndrome 5 provided a rationale for the increased malignancy risk. Further, additional gene changes affecting other components of the Ras/mitogen activated protein kinase (MAPK) pathway were found to result in the clinically related conditions-Noonan syndrome and cardio-facio-cutaneous (CFC) syndrome. These conditions are now collectively referred to as rasopathies, 6 and the improved understanding of the Ras/ MAPK pathway's primary role in embryologic development has shifted the focus from its previously well studied role in carcinogenesis. In contrast to the molecular heterogeneity of CFC and Noonan syndrome, Costello • Increased birth weight as a result of edema (not true macrosomia)
• Weight loss resulting from resolution of edema and failure to thrive the monoallelic expression in a tumor, but not in fibroblasts, reported by Aoki et al.
5
HRAS consists of six exons. Five exons [2] [3] [4] [5] [6] code for a protein of 189 amino acids with a molecular weight of 21 kd (p21). Alternative splicing, excluding residues 152-165, gives rise to a protein of 170 amino acids. Somatic mutation hotspots are bases encoding the glycines in Positions 12 and 13 and the glutamine in Position 61. Missense mutations at these positions lead to increased activity of the gene product. As the germline mutations in Costello syndrome affect similar codons, it can be inferred that they have a similar effect on the gene product. Functional studies performed on patient-derived fibroblasts confirmed aberrant downstream signaling. 19 Germline mutations leading to nucleotide substitutions and the consequent amino acid substitutions of the glycine residue at Positions 12 or 13 are typical in Costello syndrome. 20 A review of 81 unrelated individuals 5, 11, 12 shows the nucleotide substitution c.34G>A, resulting in p.Gly12Ser amino acid change, to be the most common (65/81 or 80%). The c.35G>C nucleotide resulting in p.Gly12Ala was seen in seven individuals (9%). Estep et al. 10 reported the same two mutations and aggregate clinical data on 33 individuals. In this study 11 and others conducted by colleagues, we have avoided duplicated reporting of this rare syndrome. 21 Recently, 12 individuals with p.Gly13Cys change were identified, 8 making this the most common amino acid change affecting the glycine in Position 13. Other mutations (Table 2) were seen in one or two patients each.
5,10 -12,22-25 molecular genetic testing A suspected clinical diagnosis of Costello syndrome is confirmed through the identification of a specific germline mutation in the proto-oncogene HRAS, which is the only gene associated with Costello syndrome according to a review by expert clinicians. 5, 9 Sequence analysis of HRAS exon 2 (the first coding exon) detects missense mutations in 80-90% of individuals tested. 5, [10] [11] [12] If no mutation is identified in exon 2, all other coding exons and flanking intronic regions should be sequenced, as rare mutations have been seen in other exons.
Failure to identify an HRAS mutation in an individual with a phenotype thought to be typical for Costello syndrome can result from either (1) the rare occurrence of low level of somatic mosaicism for the HRAS disease-causing mutation in the tested tissue [11] [12] [13] [14] or (2) the more common presence of a mutation in another gene, consistent with a diagnosis of CFC syndrome 15, 16 or another disorder of the Ras/MAPK pathway. 17 In the early series, the 10-15% of individuals suspected of having Costello syndrome who lacked an HRAS mutation were later found to have CFC syndrome. 15, 16 molecular genetic pathogenesis HRAS is a well-known proto-oncogene, and aberrant activation is often found in sporadic somatic tumors; it is thus not surprising to see the increased cancer incidence in individuals with a germline HRAS mutation. The work performed by Kerr et al. 18 showing loss of heterozygosity for 11p15.5 in rhabdomyosarcoma from individuals with Costello syndrome suggests that loss of the wild-type allele is the second hit in tumor development. This theory is supported by the loss of the wild-type allele in a rhabdomyosarcoma demonstrated by Estep et al. 10 and There are some changes including thinning of the frizzy hair, wrinkling of the skin, and wearing of corrective lenses. We thank the mothers of these patients for contributing their personal photographs. Permission to publish these photographs was given by the mothers. (2) c. 35_36delGCinsAA p.Gly12Glu <1 (1) c.37G>T p.Gly13Cys 1.4 (2) c.38G>A p.Gly13Asp 1.4 (2) c.64C>A p.Gln22Lys <1 (1) c.110_111+1dupAGG p.Glu37dup <1 (1) c.108_110dupAGA p.Glu37dup <1 (1) c.173C>T p.Thr58Ile <1 (1) c.187G>A p.Glu63Lys <1 (1) c.350A>G p.Lys117Arg <1 (1) c.436G>A p.Ala146Thr <1 (1) c.437C>T p.Ala146Val <1 (1) Adapted from ref. 20. genetest review atrial septal defect. Cardiac hypertrophy was noted in 61%; the term hypertrophic cardiomyopathy (HCM) was used because there was typical subaortic septal hypertrophy associated with pathologic myocardial disarray (in 70% of specimens studied). In addition to the rare lethal severe form, HCM was chronic or progressive in 37%, stabilized in 27%, decreased (resolved) in 15%; and outcome was unavailable in 22%. Atrial tachycardia occurred in 48%, characteristically as multifocal atrial tachycardia (also known as chaotic atrial rhythm). These nonreentrant atrial tachycardias are generally self-limited but may persist or worsen in approximately one fourth. Mild-moderate aortic dilation occurs in approximately 5% and was unassociated with bicuspid aortic valve. Although the cardiovascular natural history of Costello syndrome continues to be delineated, this recent data can be used to create several "cardiac phenotypes. " A few neonates present with very severe HCM can be lethal if untreated. In other infants, progressively severe HCM and/or severe multifocal atrial tachycardia can lead to death in the first 2 years of life. However, most children with Costello syndrome associated with HCM have mild to moderate involvement. Of great interest are the few with moderate to severe involvement who appear to have remodeling, which gives the impression of "normalizing. " Multifocal atrial tachycardia and ectopic atrial tachycardia may be concerning but are usually self-limited with treatment. Pulmonic valve stenosis is usually mild to moderate and infrequently requires surgery or interventional catheterization. Older individuals with moderate HCM and new onset arrhythmia (atrial and ventricular) represent the greatest challenge and do not constitute a predictable outcome "phenotype" until more information is obtained.
The possibility of a congenital myopathy in Costello syndrome was hypothesized based on the observation of four patients with severe hypotonia, three of whom had less common HRAS mutations. 22 On muscle biopsy, there were excess muscle spindles, leading to the description "congenital myopathy with excess of muscle spindles. " The analysis of skeletal muscle pathology was extended by Tidyman et al. 31 who studied additional pathology reports and muscle biopsies. They found abnormal muscle fiber size and variability, type 2 fiber predominance, but without severe structural histopathology and no excess of muscle spindles. Because Costello syndrome mutations inhibited myoblast differentiation, they agreed that there was evidence of a true myopathy related to an inherent dysregulation of skeletal myogenesis. 31 Papillomata, absent in infancy, appear in young children. Acanthosis nigricans, thick calluses and toenails, and strong body odor are common. Developmental delay or intellectual disability is present in all individuals. [32] [33] [34] [35] Electroencephalogram abnormalities are seen in approximately one third of individuals; between 20% and 50% have seizures. 36, 37 Seven of 10 individuals ages 3-29 years undergoing polysomnography in the sleep laboratory had obstructive events. 38 Dental abnormalities, including enamel defects, occur frequently. Excessive secretions are often noted. 29 Individuals with Costello syndrome have very
natural history
Females and males are equally affected. The phenotype evolves over time, and although Costello syndrome can theoretically be recognized in the fetus, it is usually diagnosed in the young child. Older individuals often display features suggestive of premature aging. Prenatally, increased nuchal thickness, polyhydramnios (>90%), characteristic ulnar deviation of the wrists, and short humeri, and femurs can be seen on ultrasonography. 26, 27 Because most features of the fetal phenotype are not unique (such as ventriculomegaly and macrocephaly), and as Costello syndrome is rare, the diagnosis is often not considered prenatally. Cardiac hypertrophy has not been reported, but fetal atrial tachycardia has been detected in at least five fetuses subsequently diagnosed with Costello syndrome, and it increases the index of suspicion for this diagnosis. 26 Increased birth weight and head circumference (often >50th percentile) for gestational age can lead to the misclassification of Costello syndrome as "macrosomia. " Hypoglycemia is common in neonates. Failure to thrive and severe feeding difficulties are usually severe and almost universal.
Characteristic physical findings include a relatively high forehead, low nasal bridge, epicanthal folds, prominent lips and a wide mouth, ulnar deviation of wrists and fingers, looseappearing skin with deep palmar and plantar creases, and cryptorchidism. In infancy, severe feeding difficulties may lead to a marasmic appearance. Pyloric stenosis occurs more commonly than in the general population. 24 Most infants display hypotonia, irritability, developmental delay, and nystagmus with delayed visual maturation improving with age. Hypotonia may be severe and suggest myopathy. 22 Relative macrocephaly is typical and likely reflects brain overgrowth. 28 Progressive postnatal cerebellar enlargement results in cerebellar tonsillar herniation, which can progress to a Chiari malformation as seen in 32% of individuals in one series, with 25% developing syringomyelia. 28 Neurosurgical interventions included posterior fossa decompression (32%), shunt placement or ventriculostomy (25%), and tethered cord release (7%), reflecting the significant morbidity associated with brain overgrowth. 28 Nystagmus is common and may improve over time, although its underlying cause has not been determined. Although nystagmus does not require medical treatment, it is important to recognize it as a common finding in Costello syndrome, rather than an unrelated symptom.
In childhood, individuals are able to take oral feeds beginning between age 2 and 4 years. The first acceptable tastes are often strong (e.g., ketchup). The onset of speech often coincides with the willingness to feed orally. Short stature is universal, delayed bone age is common, 29 and testing may show partial or complete growth hormone (GH) deficiency.
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Cardiovascular abnormalities are typically present in infancy or early childhood, but may be recognized at any age. Based on a recent analysis of 61 study and 85 previously reported patients with HRAS mutation analysis, 87% of individuals with Costello syndrome have some type of a cardiovascular abnormality, increased from a prior report based on clinically diagnosed patients (60%). 30 A congenital heart defect was present in 44%, usually nonprogressive valvar pulmonic stenosis, rarely associated with certain rare mutations, including p.Gly12Asp and p.Gly12Cys. In contrast, the possibility of a milder or attenuated phenotype was noted in individuals with p.Thr58Ile and p.Ala146Val. 24 Distinctive phenotypic findings are associated with the p.Gly13Cys change and include dolichocilia (extremely long eye lashes, often requiring trimming) and loose anagen hair. 8 Papillomata or multifocal atrial tachycardia have not yet been seen in individuals with p.Gly13Cys, and fewer have short stature. Compared with individuals with the most common p.Gly12Ser, these differences are statistically significant. In addition, no individual with p.Gly13Cys has developed a malignant tumor. 8 The two individuals reported with p.Glu37dup share phenotypic findings including very sparse hair and facial features that appear less coarse than in most other Costello syndrome individuals, but a detailed clinical description was not provided. 25 Of 146 patients with HRAS mutations whose cardiovascular status was reviewed, there was no apparent correlation between the specific mutation and the variables studied (HCM, multifocal tachycardia, and aortic dilation; Table 5 in Lin et al. 42 ). In some cases, small numbers prevented formal statistical analysis.
One individual with somatic mosaicism (20-30% of DNA derived from buccal cells exhibited the HRAS mutation p.Gly12Ser, which was not detected in DNA derived from blood cells) had an atypical phenotype attributed to her mosaicism. Findings typical for Costello syndrome included intellectual disability, short stature, sparse hair, coarse facial features, nasal papillomata, and tight Achilles tendons. Atypical findings included microcephaly, streaky areas of skin hypo-and hyperpigmentation, and normal menarche with subsequent regular menses. 44 Somatic mosaicism was seen in a father who showed a patchy distribution of skin findings suggestive of Costello syndrome and who transmitted the p.Gly12Ser change to his son with typical Costello syndrome. 13 Mosaicism for the p.Gly12Ser mutation was noted in an individual with a typical presentation including apparent cutis laxa.
14 As may be expected in an autosomal dominant trait, somatic mosaicism can thus be associated with a range of findings including patchy or segmental distribution, typical phenotypic presentation, and transmission to offspring and recurrence in siblings. 44 
treatment of manifestations
Medical care for individuals with Costello syndrome aims to improve overall health and development through early identification of anticipated medical problems and prompt treatment. Its ultimate goal is to improve quality of life for affected individuals and their families. 45 Neonatal hypoglycemia has frequently been reported, and a high level of suspicion should be maintained. Rarely, hypoglycemia occurs in older individuals and may present with seizures. Under these circumstances, GH deficiency needs to be excluded as the underlying cause. 46 Hypoglycemic episodes unresponsive to GH therapy responded well to cortisone replacement in another individual. 47 Thus, cortisol deficiency may also be considered. Because of the severe feeding difficulties, most loose joints, particularly the fingers. Ulnar deviation of the wrists and fingers is common. Achilles tendons become very tight throughout childhood and often require surgical release.
Adolescents often show delayed or disordered puberty and may appear older than their chronologic age because of worsening kyphoscoliosis, sparse hair, and prematurely aged skin. In 17 adults ranging from age 16 to 40 years, all eight individuals who had a bone density measurement had abnormal results that suggested osteoporosis or osteopenia; three had bone pain, vertebral fractures, and height loss. 39, 40 Adult-onset gastroesophageal reflux was present in four individuals in the series of White et al. 39 ; additional cases are known (personal observation). The reported adult height range is 135-150 cm. 41 
tumor predisposition
Benign and malignant solid tumors occur with far greater frequency in individuals with Costello syndrome than in the general population. The overall tumor incidence is approximately 15% over the lifetime of individuals with an identified HRAS mutation. 11 Rhabdomyosarcoma occurs most frequently, followed by neuroblastoma and transitional cell carcinoma of the bladder, and other solid tumors. 4 Rhabdomyosarcoma and neuroblastoma are tumors of early childhood, presenting in Costello syndrome at ages comparable with the general population. In contrast, transitional cell carcinoma of the bladder occurs in older adults (70%, age >65 years) in the general population, whereas it occurs in adolescents with Costello syndrome. The ages at presentation in the three reported cases were 10, 11, and 16 years.
Prevalence and mortality
A formal epidemiologic study of Costello syndrome, with lifespan analysis, survival and cumulative mortality has not been performed. Lin et al. 42 studied 146 mutation-confirmed patients, with at least another 85 clinically defined cases from the literature. The total is at least 220, and with additional unreported patients around the world, it is likely the figure approaches 300. The Costello Syndrome Family Network estimates that the birth prevalence in the United Kingdom is at least 1/500,000. 7 As part of the recent cardiovascular study, 42 deaths were reported in 10% and in the study and 20% of literature patients, providing preliminary descriptive data. Cardiorespiratory causes included HCM in all 11 (48%) accompanied by neoplasia, coronary artery fibromuscular dysplasia, and multifocal tachycardia in four. Neoplasia was noted at the cause of death in five (22%), pulmonary cause in two (9%), and multiorgan failure in five (four with HCM) (22%).
Genotype-phenotype correlations
Because few affected individuals with mutations other than p.Gly12Ser have been identified, limited genotype-phenotype correlations have been established. However, Kerr et al. 12 suggested that the risk for malignant tumors may be higher in individuals with the p.Gly12Ala mutation (4/7 or 57%) than in those with the p.Gly12Ser variant (4/65 or 7%). Lo et al. 43 suggested that a more severe neonatal phenotype may be a pediatric cardiologist, transitioning to an adult specialist following the "best practices" for the particular defect. General guidelines (Table 4 in Lin et al. 42 ) can be pragmatically dichotomized based on the presence or absence of HCM, with close evaluation in the first 2 years of life depending on the severity of hypertrophy, subsequent annual examinations, and appropriate risk stratification. We emphasized in that article and remind providers that it is beyond the scope of a genetics article to review the complex decision making for treating HCM or atrial tachycardia. The benefit of recent research 42 is that it adds modest natural history data, although ongoing studies of older individuals will be necessary to monitor for late-onset HCM progression or arrhythmia. 42 The treatment of tachycardia in Costello syndrome has not been formally studied, and anecdotal reports may not be broadly applied. Malignant nonreentrant tachycardia may require electrophysiologic catheterization, aggressive antiarrhythmic drugs, and ablation. Pharmacologic and surgical treatment (myectomy) has been used to treat severe cardiac hypertrophy. Individuals with Costello syndrome and severe cardiac problems may choose to wear a Medic Alert  bracelet. The benign papillomata usually appear in the perinasal region and less commonly in the perianal region, torso, and extremities. Although they are mostly of cosmetic concern, papillomata may give rise to irritation or inflammation in hardto-clean body regions and may be removed, as appropriate. Recurrent facial papillomata have been successfully managed with regular dry ice removal. Malignant tumors, most commonly embryonal rhabdomyosarcoma, occur with increased frequency in Costello syndrome, and this led to the proposal of a screening protocol. Abdominal and pelvic ultrasound and urine testing for catecholamine metabolites and hematuria were suggested. 48 However, a subsequent report 49 on elevated catecholamine metabolites in individuals with Costello syndrome without an identifiable tumor concluded that screening for abnormal catecholamine metabolites is not helpful. Serial abdominal and pelvic ultrasound screening for rhabdomyosarcoma and neuroblastoma was proposed every 3-6 months until age 8-10 years. Urinalysis for hematuria was suggested annually beginning at age 10 years to screen for bladder cancer. 48 Neither of these screening approaches has yet been proven to be beneficial; however, studies are ongoing. The most important factor for early tumor detection remains parental and physician awareness of the increased cancer risk. Treatment of malignant tumors follows standard protocols. the rasopathies clinic: a pragmatic care model Costello syndrome affects multiple organ systems and requires medical care expertise from numerous specialty areas, including cardiology, gastroenterology, neurology and neurosurgery, orthopedics, urology, developmental medicine and therapeutic services, and often oncology. With approximately 300 reported patients, Costello syndrome remains rare, and most specialists will see very few affected individuals throughout their career and will thus have little personal experience with this condition. infants require nasogastric or gastrostomy feeding. Because of gastroesophageal reflux and irritability, Nissen fundoplication is often performed. Pyloric stenosis is treated surgically. Severe irritability associated with feeding and an inability to sleep has anecdotally improved by use of benzodiazepines, resulting in decreased irritability and weight gain. Anecdotally, affected children have very high caloric needs. Even after nutrition is improved through supplemental feeding, growth retardation persists. GH deficiency can often be documented on stimulation testing and warrants replacement therapy. Although linear growth may benefit from GH replacement, the main objective of replacement therapy is to prevent secondary complications, such as hypoglycemia and low muscle mass. Orthopedic issues can include congenital hip dysplasia, scoliosis, and kyphoscoliosis. Joint contractures, often affecting elbows, wrists, and fingers are treated through physical and occupational therapy or by early bracing. Surgical tendon lengthening, usually of the Achilles tendon, is often required in late childhood. Low bone density is common in young adults with Costello syndrome; and bone density assessment is recommended as a baseline, with follow-up depending on the initial result. Osteoporosis may be ameliorated by physical activity and increased vitamin D and calcium intake, or require treatment with pamidronate.
The high risk for postnatal development of a Chiari I malformation and its sequelae warrant a brain imaging study, preferably a magnetic resonance imaging, at the time of diagnosis and a repeat scan 1-2 years later or whenever the patient becomes symptomatic. 28 In older individuals, headaches, changes in gait, and other neurologic symptoms may prompt imaging of the central nervous system and spinal cord. A symptomatic Chiari I malformation will require surgical intervention, typically a posterior fossa decompression. Tethered cord is common in individuals with Costello syndrome and may present with loss of bowel and bladder function or gait disturbance, it is treated surgically. Developmental disability should be addressed by early-intervention programs and individualized learning strategies. Speech delay and expressive language limitations will benefit from appropriate therapy and an appropriate educational plan. As for every individual with developmental delay, an eye and hearing evaluation is indicated, and medical problems are treated as necessary. Alternate means of communication should be considered if expressive language is significantly limited. Anxiety occurs more frequently than in the general population, and it may benefit from supportive therapies, appropriate educational expectations, and use of standard medications. The identification of individual cognitive and adaptive strengths, and the development of an educational plan building on these strengths, may improve independent living skills and will result in improved quality of life.
We continue to recommend that all individuals with Costello syndrome, especially those with an identified cardiovascular abnormality, should be followed up by a cardiologist who is aware of the spectrum of cardiac disease and its natural history. 30, 42 Rather than propose a unique set of guidelines, we advise providers and families to receive individualized care by
